Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

31 results about "Bladder Disorder" patented technology

A non-neoplastic or neoplastic disorder affecting the urinary bladder. A representative example of non-neoplastic bladder disorder is bacterial bladder infection. A representative example of neoplastic bladder disorder is bladder carcinoma.

Novel agents for preventing and treating disorders involving modulation of the RyR receptors

The present invention provides novel compounds of Formula I and salts, hydrates, solvates, complexes, and prodrugs thereof. The present invention further provides methods for synthesizing compounds of Formula I. The invention additionally provides pharmaceutical compositions comprising the compounds of Formula I and methods of using the pharmaceutical compositions of Formula I to treat and prevent disorders and diseases associated with the RyR receptors that regulate calcium channel functioning in cells. Such disorders and diseases include, by way of example only, cardiac disorders and diseases, skeletal muscular disorders and diseases, cognitive disorders and diseases, malignant hyperthermia, diabetes, and sudden infant death syndrome. Cardiac disorder and diseases include, but are not limited to, irregular heartbeat disorders and diseases; exercise-induced irregular heartbeat disorders and diseases; sudden cardiac death; exercise-induced sudden cardiac death; congestive heart failure; chronic obstructive pulmonary disease; and high blood pressure. Irregular heartbeat disorders and diseases include and exercise-induced irregular heartbeat disorders and diseases include, but are not limited to, atrial and ventricular arrhythmia; atrial and ventricular fibrillation; atrial and ventricular tachyarrhythmia; atrial and ventricular tachycardia; catecholaminergic polymorphic ventricular tachycardia (CPVT); and exercise-induced variants thereof. Skeletal muscular disorder and diseases include, but are not limited to, skeletal muscle fatigue, exercise-induced skeletal muscle fatigue, muscular dystrophy, bladder disorders, and incontinence. Cognitive disorders and diseases include, but are not limited to, Alzheimer's Disease, forms of memory loss, and age-dependent memory loss.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK

Novel agents for preventing and treating disorders involving modulation of the RyR receptors

The present invention provides novel compounds of Formula I and salts, hydrates, solvates, complexes, and prodrugs thereof. The present invention further provides methods for synthesizing compounds of Formula I. The invention additionally provides pharmaceutical compositions comprising the compounds of Formula I and methods of using the pharmaceutical compositions of Formula I to treat and prevent disorders and diseases associated with the RyR receptors that regulate calcium channel functioning in cells. Such disorders and diseases include, by way of example only, cardiac disorders and diseases, skeletal muscular disorders and diseases, cognitive disorders and diseases, malignant hyperthermia, diabetes, and sudden infant death syndrome. Cardiac disorder and diseases include, but are not limited to, irregular heartbeat disorders and diseases; exercise-induced irregular heartbeat disorders and diseases; sudden cardiac death; exercise-induced sudden cardiac death; congestive heart failure; chronic obstructive pulmonary disease; and high blood pressure. Irregular heartbeat disorders and diseases include and exercise-induced irregular heartbeat disorders and diseases include, but are not limited to, atrial and ventricular arrhythmia; atrial and ventricular fibrillation; atrial and ventricular tachyarrhythmia; atrial and ventricular tachycardia; catecholaminergic polymorphic ventricular tachycardia (CPVT); and exercise-induced variants thereof. Skeletal muscular disorder and diseases include, but are not limited to, skeletal muscle fatigue, exercise-induced skeletal muscle fatigue, muscular dystrophy, bladder disorders, and incontinence. Cognitive disorders and diseases include, but are not limited to, Alzheimer's Disease, forms of memory loss, and age-dependent memory loss.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK

Non-invasive electrical and magnetic nerve stimulators used to treat overactive bladder and urinary incontinence

Transcutaneous electrical and magnetic nerve stimulation devices and methods generate energy that is delivered noninvasively to selected nerve fibers within the patient to treat lower urinary tract disorders. The disorders comprise overactive bladder, urge incontinence, stress, incontinence, urge frequency, non-obstructive urinary retention and interstitial cystitis / painful bladder syndrome. In preferred embodiments, a posterior tibial nerve of a patient is stimulated non-invasively to treat bladder disorders.
Owner:ELECTROCORE

Sphingomyelin liposomes for the treatment of hyperactive bladder disorders

InactiveUS20070122466A1Reduce and prevent antibody-mediated resistanceIncrease stimulationLiposomal deliveryAgainst vector-borne diseasesDiseaseLipid formation
The present invention provides pharmaceutical compositions and methods for the instillation of lipid vehicles comprised of liposomes containing sphingomyelin or sphingomyelin metabolites to prevent, manage, ameliorate and / or treat disorders involving neuropathic pain and aberrant muscle contractions, such as what occurs in bladder hyperactivity disorders such as interstitial cystitis (IC) in animals or humans in need thereof. Also provided is a liposome-based delivery of drugs, e.g., antibiotics, pain treatments and anticancer agents, to the bladder, genitourinary tract, gastrointestinal system, pulmonary system and other organs or body systems. In particular, liposome-based delivery of vanilloid compounds, such as resiniferatoxin, capsaicin, or tinyatoxin and toxins, such as botulinum toxin is provided for the treatment of bladder conditions, including pain, inflammation, incontinence and voiding dysftunction.
Owner:UNIVERSITY OF PITTSBURGH

Detection of neureopeptides associated with pelvic pain disorders and uses thereof

Diagnostic assessment and therapeutic treatment of pelvic pain disorders, including bladder disorders, bowel disorders, and / or reproductive tissue or organ disorders that are characterized by increased expression of the neuropeptides CGRP and / or PACAP. Additionally, applicants have developed a transgenic nonhuman model for pelvic pain disorders, where the transgenic animal expresses in bladder sensory neurons a recombinant neuropeptide implicated in the pelvic pain disorder.
Owner:UNIVERSITY OF VERMONT +1

Compositions and methods for the modulation of detrusor activity

InactiveUS20080089884A1BiocideSsRNA viruses positive-senseMIF receptorMacrophage migration inhibition
The invention relates generally to methods for treating and / or preventing bladder disorders. In certain embodiments the invention comprises methods for the treatment and / or prevention of a bladder disorder comprising administering an effective amount of a therapeutic agent that decreases the expression, release or biological activity of macrophage migration inhibition factor (MIF) to a subject in need thereof. In other aspects the invention relates to a method for diagnosing bladder disease and / or bladder disease severity comprising screening for a MIF gene or MIF receptor gene polymorphism or expression level.
Owner:YALE UNIV +1

Detection of neuropeptides associated with pelvic pain disorders and uses thereof

InactiveUS20120058950A1Effective to treat the pelvic pain disorderRelieve symptomsBiocideOrganic active ingredientsDense Core VesiclesSensory neuron
Diagnostic assessment and therapeutic treatment of pelvic pain disorders, including bladder disorders, bowel disorders, and / or reproductive tissue or organ disorders that are characterized by increased expression of the neuropeptides CGRP and / or PACAP. Additionally, applicants have developed a transgenic non-human model for pelvic pain disorders, where the transgenic animal expresses in bladder sensory neurons a recombinant neuropeptide implicated in the pelvic pain disorder.
Owner:UNIVERSITY OF VERMONT +1

Penisster system

InactiveUS20020134389A1Pleasant for wearerComfortably insertedMale contraceptivesSurgeryDiseasePenis
The medical system 10 is an article of cloth, rubber and elastic made in the style of a pair of briefs, the front of the system 10 is made of a rubber material in the form of a shield 40 covered with cloth to protect direct contact from bodies of both partners in case of sexual activities. Attached to the shield 40 is namely a hollow tubal-shaped device 42 to be worn over the penis. The tubal-shaped device 42 has a nipple 53 at the end and can be used for sexual activities. The medical system 10 a pouch 56 beneath tubular-shaped device 42 to store device 42. Persons with prostate and bladder disorder may also use this medical system 10 for incontinence.
Owner:BADGETT HENRY O

Agents for preventing and treating disorders involving modulation of the RyR receptors

The present invention provides novel compounds of Formula Iand salts, hydrates, solvates, complexes, and prodrugs thereof. The present invention further provides methods for synthesizing compounds of Formula I. The invention additionally provides pharmaceutical compositions comprising the compounds of Formula I and methods of using the pharmaceutical compositions of Formula I to treat and prevent disorders and diseases associated with the RyR receptors that regulate calcium channel functioning in cells. Such disorders and diseases include, by way of example only, cardiac disorders and diseases, skeletal muscular disorders and diseases, cognitive disorders and diseases, malignant hyperthermia, diabetes, and sudden infant death syndrome. Cardiac disorder and diseases include, but are not limited to, irregular heartbeat disorders and diseases; exercise-induced irregular heartbeat disorders and diseases; sudden cardiac death; exercise-induced sudden cardiac death; congestive heart failure; chronic obstructive pulmonary disease; and high blood pressure. Irregular heartbeat disorders and diseases include and exercise-induced irregular heartbeat disorders and diseases include, but are not limited to, atrial and ventricular arrhythmia; atrial and ventricular fibrillation; atrial and ventricular tachyarrhythmia; atrial and ventricular tachycardia; catecholaminergic polymorphic ventricular tachycardia (CPVT); and exercise-induced variants thereof. Skeletal muscular disorder and diseases include, but are not limited to, skeletal muscle fatigue, exercise-induced skeletal muscle fatigue, muscular dystrophy, bladder disorders, and incontinence. Cognitive disorders and diseases include, but are not limited to, Alzheimer's Disease, forms of memory loss, and age-dependent memory loss.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK

Agents for preventing and treating disorders involving modulation of the RyR receptors

The present invention provides novel compounds of Formula Iand salts, hydrates, solvates, complexes, and prodrugs thereof. The present invention further provides methods for synthesizing compounds of Formula I. The invention additionally provides pharmaceutical compositions comprising the compounds of Formula I and methods of using the pharmaceutical compositions of Formula I to treat and prevent disorders and diseases associated with the RyR receptors that regulate calcium channel functioning in cells. Such disorders and diseases include, by way of example only, cardiac disorders and diseases, skeletal muscular disorders and diseases, cognitive disorders and diseases, malignant hyperthermia, diabetes, and sudden infant death syndrome. Cardiac disorder and diseases include, but are not limited to, irregular heartbeat disorders and diseases; exercise-induced irregular heartbeat disorders and diseases; sudden cardiac death; exercise-induced sudden cardiac death; congestive heart failure; chronic obstructive pulmonary disease; and high blood pressure. Irregular heartbeat disorders and diseases include and exercise-induced irregular heartbeat disorders and diseases include, but are not limited to, atrial and ventricular arrhythmia; atrial and ventricular fibrillation; atrial and ventricular tachyarrhythmia; atrial and ventricular tachycardia; catecholaminergic polymorphic ventricular tachycardia (CPVT); and exercise-induced variants thereof. Skeletal muscular disorder and diseases include, but are not limited to, skeletal muscle fatigue, exercise-induced skeletal muscle fatigue, muscular dystrophy, bladder disorders, and incontinence. Cognitive disorders and diseases include, but are not limited to, Alzheimer's Disease, forms of memory loss, and age-dependent memory loss.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK

Prevention and Treatment of Gastrointestinal and Bladder Disorders Associated with Chemotherapy or Radiation Therapy Using Active Vitamin D Compounds

The present invention relates to a method for preventing, treating, or ameliorating gastrointestinal and bladder disorders in a patient receiving a chemotherapy or radiation therapy comprising administering to the patient a therapeutically effective amount of active vitamin D compound or a mimic thereof. According to the invention, the active vitamin D compound or a mimic thereof may be administered by high dose pulse administration so that high doses of the active vitamin D compound or a mimic thereof can be administered to an animal without inducing severe symptomatic hypercalcemia.
Owner:NOVACEA INC

Sphingomyelin liposomes for the treatment of hyperactive bladder disorders

InactiveUS20170290773A1Reduce and prevent antibody-mediated resistanceIncrease stimulationUrinary disorderLiposomal deliveryDiseaseMetabolite
The present invention provides pharmaceutical compositions and methods for the instillation of lipid vehicles comprised of liposomes containing sphingomyelin or sphingomyelin metabolites to prevent, manage, ameliorate and / or treat disorders involving neuropathic pain and aberrant muscle contractions, such as what occurs in bladder hyperactivity disorders such as interstitial cystitis (IC) in animals or humans in need thereof. Also provided is a liposome-based delivery of drugs, e.g., antibiotics, pain treatments and anticancer agents, to the bladder, genitourinary tract, gastrointestinal system, pulmonary system and other organs or body systems. In particular, liposome-based delivery of vanilloid compounds, such as resiniferatoxin, capsaicin, or tinyatoxin and toxins, such as botulinum toxin is provided for the treatment of bladder conditions, including pain, inflammation, incontinence and voiding dysfunction.
Owner:UNIVERSITY OF PITTSBURGH

Reverse thermal hydrogel preparations for use in the treatment of disorders of the urothelium

A method for maintaining and / or enhancing the efficacy of a pharmaceutically active agent in a sustained-release treatment of a bladder disorder is disclosed. In preferred embodiments, the pharmaceutically active agent is botulinum toxin. The method comprises obtaining a biocompatible mucoadhesive thermoreversible hydrogel; and incorporating said pharmaceutically active agent for treatment of a bladder disorder into said biocompatible mucoadhesive thermoreversible hydrogel. The use of a biocompatible mucoadhesive thermoreversible hydrogel comprising a pharmaceutically active agent such as botulinum toxin in the treatment of bladder disorders, and a method for treating bladder disorders by the use of such a composition that does not require injection of the pharmaceutically active agent into the bladder wall, are also disclosed.
Owner:THERACOAT

Pharmaceutical composition for the treatment of bladder disorders

The invention relates to pharmaceutical compositions with activity against disorders of urogenital system of mammals which comprises a zinc-hyaluronan complex as active ingredient and a pharmaceutically acceptable carrier and / or additive. The process for the preparation of said pharmaceutical compositions as well as the therapeutic use thereof for the treatment and prevention of diseases associated with abnormalities and deficiencies of glucosaminoglycan (GAG) layer in the urogenital system in mammals and a kit comprising zinc hyaluronate solution, a catheter which is applicable to intravesical administration and optionally a balloon which is applicable to bladder dillatation are also within the scope of the invention.
Owner:RICHTER GEDEON NYRT

Methods of treating bladder disorders

InactiveUS20050282763A1Reduced antibody productionReduced histamine releaseDepsipeptidesGranular deliveryBladder cancerMammal
Methods of treating bladder disorders, including bladder cancer and inflammatory bladder diseases such as interstitial cystitis are disclosed. The methods include identifying a mammal that has or is at risk for having a bladder disorder and administering isolated nucleic acid sequences to the mammal. Nucleic acids used in the methods of the invention contain unmethylated CpG sequences, which are thought to modulate the immune response. Also included are methods that use nucleic acids encoding alpha-MSH. The nucleic acid sequences may be administered individually or together or can be included in the same nucleic acid.
Owner:ZYCOS A MASSACHUSETTS CORP

Pharmaceutical composition for the treatment of bladder disorders

The invention relates to pharmaceutical compositions with activity against disorders of urogenital system of mammals which comprises a zinc-hyaluronan complex as active ingredient and a pharmaceutically acceptable carrier and / or additive. The process for the preparation of said pharmaceutical compositions as well as the therapeutic use thereof for the treatment and prevention of diseases associated with abnormalities and deficiencies of glucosaminoglycan (GAG) layer in the urogenital system in mammals and a kit comprising zinc hyaluronate solution, a catheter which is applicable to intravesical administration and optionally a balloon which is applicable to bladder dillatation are also within the scope of the invention.
Owner:RICHTER GEDEON NYRT

Bladder disease monitor

The invention provides a bladder disease monitor, and belongs to the technical field of medical equipment. The bladder disease monitor comprises a lithium ion battery, a sensor conditioning circuit, acontroller and a touch display screen; the lithium ion battery is connected with a 5V voltage stabilizing circuit, and the 5V voltage stabilizing circuit is connected with a resistor stress sensor, adifferential full-bridge conditioning circuit, a 24-bit AD conversion module and a 32-bit single chip controller; the 32-bit single chip controller is connected with the 24-bit AD conversion module,the touch screen and an external storage; and the lithium ion battery provides a portable rechargeable power source for a whole system, through an SD card storage technology, the system can store larger volume of data, and the stability and reliability of data storage are improved. The bladder disease monitor is novel in module structure and clear in working principle, design is conducted by taking the single chip microcomputer STM32F103RCT6 as a core, operation is easy and convenient, trauma is small, the cost is low, the bladder pressure is monitored on line, the bladder disease monitor hasthe advantages of short measuring time, accurate data, high automatic degree and the like, medical workers grasp the condition of patients in time conveniently, and the great application value is achieved.
Owner:徐州天荣医疗通讯设备有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products